About Cellular Engineering Technologies
Cellular Engineering Technologies is a company based in Coralville (United States) founded in 2000 by Alan Moy. Cellular Engineering Technologies has raised $45 thousand across 3 funding rounds from investors including HHS. Cellular Engineering Technologies offers products and services including Human iPSC Reprogramming Kit, Human iPSC Growth Media Kit, Human Recombinant BDNF Protein, and Human Wharton’s Jelly-Derived Mesenchymal Stem Cells. Cellular Engineering Technologies operates in a competitive market with competitors including Multus, Metatissue, Nu-Tek Biosciences, Kohjin Bio and Sarvoshadhi Bio, among others.
- Headquarter Coralville, United States
- Founders Alan Moy
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cellular Engineering Technologies, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$45 K (USD)
in 3 rounds
-
Latest Funding Round
$721.02 K (USD), Grant
Aug 15, 2020
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cellular Engineering Technologies
Cellular Engineering Technologies offers a comprehensive portfolio of products and services, including Human iPSC Reprogramming Kit, Human iPSC Growth Media Kit, Human Recombinant BDNF Protein, and Human Wharton’s Jelly-Derived Mesenchymal Stem Cells.
Kit for efficient reprogramming of cells into iPSCs for research purposes
Media formulation to support iPSC expansion and maintenance
Protein for enhancing cell growth in research applications
Cells derived for use in disease modeling and therapy research
Funding Insights of Cellular Engineering Technologies
Cellular Engineering Technologies has successfully raised a total of $45K across 3 strategic funding rounds. The most recent funding activity was a Grant round of $721.02 thousand completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cellular Engineering Technologies
Cellular Engineering Technologies has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Cellular Engineering Technologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cellular Engineering Technologies
Investment portfolio details for Cellular Engineering Technologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cellular Engineering Technologies
Detailed financials for Cellular Engineering Technologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellular Engineering Technologies Comparisons
Peer comparison for Cellular Engineering Technologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cellular Engineering Technologies
Cellular Engineering Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Multus, Metatissue, Nu-Tek Biosciences, Kohjin Bio and Sarvoshadhi Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of lab-grown meat alternatives
|
|
| Locked | Locked | Locked |
Provider of human protein-based products for cell culture, tissue engineering, and disease modeling applications
|
|
| Locked | Locked | Locked |
Develops innovative animal-free peptones and cell culture media for pharmaceutical use.
|
|
| Locked | Locked | Locked |
Tissue culture media provided for regenerative medicine and immunotherapy research.
|
|
| Locked | Locked | Locked |
Customized cell culture media for biotechnology are developed.
|
|
| Locked | Locked | Locked |
Developer of cell culture medium for pharmaceutical screening and personalized medicine
|
Detailed competitors of Cellular Engineering Technologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellular Engineering Technologies
Complete news archive for Cellular Engineering Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellular Engineering Technologies
Cellular Engineering Technologies was founded in 2000 and raised its 1st funding round 11 years after it was founded.
Cellular Engineering Technologies is headquartered in Coralville, United States. It is registered at Coralville, Iowa, United States.
Marc J Centrella is the current CEO of Cellular Engineering Technologies.
Cellular Engineering Technologies is a funded company, having raised a total of $45K across 3 funding rounds to date.
Cellular Engineering Technologies was founded in 2000 and is based in Coralville, United States. Operations focus on the biotechnology sector, where induced pluripotent stem cells, media formulations, and growth factor proteins are provided. These resources support researchers and process development professionals in cell-based studies. Services aim to facilitate research acceleration without direct involvement in clinical applications.
Cellular Engineering Technologies's top competitors include Multus, Onkologic and Metatissue.
Cellular Engineering Technologies offers Human iPSC Reprogramming Kit, Human iPSC Growth Media Kit, Human Recombinant BDNF Protein, and Human Wharton’s Jelly-Derived Mesenchymal Stem Cells.
Cellular Engineering Technologies has 1 investor. Key investors include HHS.